Remove .Net Remove Sales Remove Thousand Oaks
article thumbnail

Amgen Acquires Otezla for $13.4 Billion

socalTECH

Thousand Oaks-based Amgen announced this morning that it is acquiring Otezla , the anti-inflammatory drug used to treat psoriasis and psoriatic arthritis, which is currently owned by Celgene Corporation , in a deal worth $13.4 billion net of anticipated future cash tax benefits. billion in sales in 2018. billion in cash.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. Frank Vinluan has more on Novan, which relied on a variety of high net worth individuals, rather than venture firms, to get to this point.

Pricing 40